Cancer Letters
Volume 286, Issue 1 , Pages 38-43 , 1 December 2009

Hepatic iron overload and hepatocellular carcinoma

Received 15 February 2008 ,Accepted 4 November 2008.

References 

  1. Strohmeyer G, Niederau C, Stremmel W. Survival and causes of death in hemochromatosis: observations in 163 patients. Ann. N.Y. Acad. Sci. 1988;526:245–257
  2. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and non-cirrhotic patients with primary hemochromatosis. N. Engl. J. Med. 1985;313:1256–1262
  3. Bradbear R, Bain C, Siskind V, Schofield F, Webb S, Axelsen E, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic non-alcoholic liver diseases. J. Natl. Cancer Inst. 1985;75:81–84
  4. Bothwell TH, Bradlow BA. Siderosis in the Bantu: a combined histopathological and chemical study. Arch. Path. 1960;70:279–292
  5. Bothwell TH, Isaacson C. Siderosis in the Bantu: a comparison of incidence in males and females. Br. Med. J. 1962;1:522–524
  6. Friedman BM, Baynes RD, Bothwell TH, Gordeuk VR, MacFarlane BJ, Lamparelli RD, et al. Dietary iron overload in southern African rural blacks. S. Afr. Med. J. 1990;78:301–305
  7. Higginson J. Primary carcinoma of the liver in Africa. Br. J. Cancer. 1956;10:609–622
  8. Higginson J. Pathogenesis of liver cancer in the Johannesburg area (S. Africa). Acta Unio Internationalis Contra Cancrum. 1957;13:590–598
  9. Higginson J. The geographic pathology of primary liver cancer. Cancer Res. 1963;23:1624–1633
  10. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel D, Bothwell TH. Associations of iron overload in Africa and hepatocellular carcinoma and tuberculosis. Blood. 1996;87:3470–3476
  11. Moyo VM, Makinuke R, Gangaudzo IT, Gordeuk VR, McLaren VR, Khumalo H, et al. African iron overload and hepatocellular carcinoma. Eur. J. Haematol. 1998;60:28–34
  12. Mandishoma E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, Rouault TA, et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology. 1998;27:1563–1566
  13. Asare GA, Paterson AC, Kew MC, Khan S, Mossanda KS. Iron-free neoplastic nodules and hepatocellular carcinoma without cirrhosis in Wistar rats fed a diet high in iron. J. Pathol. 2006;208:82–90
  14. Asare GA, Mossanda KS, Kew MC, Paterson AC, Kahler-Venter CP, Siziba K. Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity. Toxicology. 2006;219:41–52
  15. Hsing AW, McLaughlin JK, Olsen SH, Mellemkjar L, Waholder S, Fraumeni JF. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int. J. Cancer. 1995;60:160–162
  16. Adams PC. Hepatocellular carcinoma in hereditary hemochromatosis. Can. J. Gastroenterol. 1998;129:946–995
  17. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127:S79–S86
  18. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology. 1991;101:368–372
  19. Bomford A, Williams R. Long-term results of venesection therapy in idiopathic hemochromatosis. Quart. J. Med. 1967;45:611–623
  20. Kew MC, Popper H. The relationship between hepatocellular carcinoma and cirrhosis. Semin. Liver Dis. 1984;4:136–146
  21. Purtilo DT, Gottlieb LS. Cirrhosis and hepatoma occurring at Boston City Hospital (1917–1968). Cancer. 1973;32:458–462
  22. MacSween RN, Scott AR. Hepatic fibrosis: a clinico-pathological review of 520 cases. J. Clin. Pathol. 1973;26:9369–9942
  23. Blumberg RS, Chopra S, Ibrahim R, Crawford J, Farraye Y, Zeldis JB, et al. Primary hepatocellular carcinoma in idiopathic hemochromatosis: occurrence in non-cirrhotic patients. Gastroenterology. 1988;95:1399–1402
  24. Deugnier Y, Turlin B. Iron and neoplasia. J. Hepatol. 1998;28:21–25
  25. Goh J, Callagy G, McEntee G, O’Keane JC, Bomford A, Crowe J. Hepatocellular carcinoma arising in a non-cirrhotic liver in genetic hemochromatosis: three case reports and a review of the literature. Eur. J. Gastroenterol. 1999;11:915–919
  26. Kohler HH, Hohler T, Kusel U, Kirkpatrick CJ, Schirmacher P. Hepatocellular carcinoma in a patient with hereditary hemochromatosis and non-cirrhotic liver. A case report. Pathol. Res. Pract. 1999;195:509–513
  27. Pelisse M, Gonzalez-Abraldes J, Navas M, Miquel B, Bruguera M. Hepatocellular carcinoma in a patient with hereditary hemochromatosis without cirrhosis. Gastroenterol. Hepatol. 2001;234:132–134
  28. Britto MR, Thomas LA, Balaratnam N, Griffiths AP, Duane PD. Hepatocellular carcinoma arising in a non-cirrhotic liver in genetic hemochromatosis. Scand. J. Gastroenterol. 2000;35:889–893
  29. Francanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001;33:647–665
  30. A.S. Strachan, Hemosiderosis and hemochromatosis in South African natives with a comment on the aetiology of hemochromatosis, MD Thesis, University of Glasgow, Glasgow, Scotland, 1929.
  31. Walker ARP, Arvidsson UB. Iron overload in the South African Bantu. Trans. Roy. Soc. Trop. Med. Hyg. 1953;47:536–548
  32. Gordeuk VR, Boyd RD, Brittenham GM. Dietary iron overload persists in rural sub-Saharan Africa. Lancet. 1986;1:1310–1313
  33. Moyo VM, Gangaidzo IT, Gomo ZA, Khumalo H, Saungweme T, Kiire CF, et al. Traditional beer consumption and the iron status of spouse pairs from a rural community in Zimbabwe. Blood. 1997;89:2159–2166
  34. MacPhail AP, Simon MO, Torrance JD, Charlton RW, Isaacson C, Bothwell TH. Changing patterns of dietary iron overload in Black South Africans. Am. J. Clin. Nutr. 1979;32:1272–1278
  35. Bothwell TH, Seftel H, Jacobs P, Torrance JD, Baumslag N. Iron overload in Bantu subjects. Studies on the availability of iron in Bantu beer. Am. J. Clin. Nutr. 1964;14:47–51
  36. MacPhail AP, Mandishona E, Bloom P, Paterson AC, Rouault TA, Gordeuk VR. Measurements of iron status and survival in African iron overload. S. Afr. Med. J. 1999;89:966–972
  37. Bothwell TH, Isaacson C. Siderosis in the Bantu: a comparison of incidence in males and females. Br. Med. J. 1962;1:522–524
  38. Chapman RW, Morgan MY, Laulicht M, Hoffbrand AV, Sherlock S. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig. Dis. Sci. 1982;27:909–916
  39. Valberg LS, Simon JB, Manley PM, Corbett WE, Ludwig J. Distribution of storage iron as body stores expand in patients with hemochromatosis. J. Lab. Clin. Med. 1975;86:479–489
  40. Brink B, Disler P, Lynch SR, Jacobs P, Charlton RW, Bothwell TH. Patterns of iron storage in dietary iron overload and idiopathic hemochromatosis. J. Lab. Clin. Med. 1976;88:725–731
  41. Isaacson C, Seftel HC, Keeley KJ, Bothwell TH. Siderosis in the Bantu: the relationship between iron overload and cirrhosis. J. Lab. Clin. Med. 1961;58:845–853
  42. Gordeuk VR, Mukiibi J, Hassstedt SJ, Samowitz W, Edwards SQ, West G, et al. Iron overload in Africa: interaction between a gene and dietary iron content. N. Engl. J. Med. 1992;326:95–100
  43. Gonzales J, Benirchke K, Saltman P, Roberts J, Robinson P. Haemosiderosis in lemurs. Zoo. Biol. 1984;3:255–265
  44. Randel MG, Patnaik AK, Gould WJ. Hepatopathy associated with excessive iron storage in Mynah birds. J. Am. Vet. Med. Assoc. 1981;179:1214–1217
  45. Rothenberg BE, Voland JR. Beta 2 knockout mice develop parenchymal iron overload: a putative role for class 1 genes of the major histocompatibility complex in iron metabolism. Proc. Natl. Acad. Sci. USA. 1996;93:1529–1534
  46. Barry M, Tavill AS, Brittenham GM, Park CH, Ross CF, Williams R. Hereditary spherocytosis with secondary hemochromatosis. Lancet. 1968;2:481–485
  47. Chung H, Kudo M, Kawasaki T, Kitanio M, Minami Y, Suetomi Y, et al. Hepatocellular carcinoma associated with secondary hemochromatosis in a non-cirrhotic liver: a case report. Hepatol. Res. 2003;26:254–258
  48. Borgna-Pignatti C, Vergine G, Lombardo T, Capellini MD, Cianciullui P, Maggio A, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br. J. Haematol. 2004;124:114–117
  49. Blanc JF, De Ledinghen V, Bernard PH, de Verneuil H, Winnock M, Le Bail B, et al. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J. Hepatol. 2000;32:805–8112000
  50. Bralet MP, Regimbeau JM, Pineau P, Dubois S, Loas G, Degos F, et al. Hepatocellular carcinoma occurring in non-fibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology. 2000;32:200–204
  51. Park CH, Bacon BR, Brittenham GM, Tavill AS. Pathology of dietary carbonyl iron overload in rats. Lab. Invest. 1987;57:555–563
  52. Iancu TC, Ward RJ, Peters TJ. Ultrastructural observation in the carbonyl iron fed rat: an animal model for hemochromatosis. Virchows Arch. B. 1987;53:208–217
  53. Ward RJ, Florence AL, Baldwin D, Abiaka C, Roland F, Ramsey MH, et al. Biochemical and biophysical investigations of the ferrocen iron-loaded rat. An animal model of primary hemochromatosis. Eur. J. Biochem. 1991;202:405–410
  54. Dullman J, Wulfhekel U, Nielsen P, Heinrich HC. Iron overload of the liver by trimethyl hexanoyl ferrocene in rats. Acta Anat. 1992;43:96–108
  55. Nielsen P, Heinrich HC. Metabolism of iron from (3, 3, 5-trimethyl hexanoyl) ferrocene in rats. Biochem. Pharmacol. 1993;45:385–391
  56. Deugnier YM, Charambalous P, Le Quilleuc D, Turlin B, Searle J, Brissot P, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 85 patients. Hepatology. 1993;18:1363–1369
  57. Tatematsu M, Tsuda H, Shirai T, Matsui T, Ito N. Placental glutathione S transferase as a new marker for hepatocarcinogenesis: in vivo short-term screening for hepatocarcinogenesis. Toxicol. Pathol. 1986;15:60–68
  58. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int. 2005;25:16–27
  59. Meneghini R. Iron homeostasis, oxidative stress, and DNA damage. Free Radic. Biol. Med. 1997;23:783–792
  60. Jungst C, Cheng B, Gehrke R, Schmitz V, Nischalke HD, Ramakers J, et al. Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology. 2004;39:1663–1672
  61. Loeb LA, James EA, Waltersdorph AM, Klebanofrf SJ. Mutagenesis by the autoxidation of iron with isolated DNA. Proc. Natl. Acad. Sci. USA. 1988;85:3918–3932
  62. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free. Radic. Biol. Med. 1991;11(1):81–128
  63. Esterbauer H. Cytotoxicity and genotoxicity of lipid-oxidation products. Am. J. Clin. Nutr. 1993;57(Suppl.):779–860
  64. Cheeseman KH. Lipid peroxidation in cancer. In:  Halliwell B,  Arouma AI editor. DNA and Free Radicals. London: Ellis Horwood; 1993;p. 109–144
  65. Cadenzas E. Biochemistry of oxygen toxicity. Ann. Rev. Biochem. 1989;58:79–110
  66. Benhar M, Engelberg D, Levitzki A. Reactive oxygen stress, stress-activated kinases and stress signalling in cancer. EMBO Rep. 2002;3:420–425
  67. Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, et al. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA. 1994;91:12808–12812
  68. Wacker M, Wanek P, Eder E. Detection of 1, N2-propanodeoxyguanosine adducts of trans-4-hydroxy-2-nonenal after gavage of trans-4-hydroxy-2-nonenal or induction of lipid peroxidation with carbon tetrachloride in F344 rats. Chem. Biol. Interact. 2001;137(3):269–283
  69. Dabbagh AJ, Mannion T, Lynch SM, et al. The effect of iron overload on rat plasma and liver oxidant status. In vivo Biochem. J. 1994;300:799–803
  70. Cheng KC, Cahill DS, Kasai H, et al. 8-Hydroxyl guanine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions. J. Biol. Chem. 1992;267:166–172
  71. Ichiba M, Maeta Y, Mukoyama T, et al. Expression of 8-hydroxy-2′-deoxyguanosine in chronic liver disease and hepatocellular carcinoma. Liver Int. 2003;23:1781–1789
  72. Orimo H, Toura Y, Hino R, Kasai H. Formation of 8-hydroxy-2′-deoxyguanosine in the DNA of cultured keratinocytes by clinically used doses of narrowband and broadband B and psoralen plus ultraviolet light. Cancer Sci. 2006;97:99–105
  73. Kuchino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K. Misreading of DNA templates containing 8-hydroxydeoxguanosine at the modifies base and at adjacent residues. Nature. 1989;327(6117):77–79
  74. Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R. P53 mutations in British patients withy hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology. 1999;117:154–160
  75. Marrogi AJ, Khan MA, van Gijssel HE, Welsh JA, Rahim H, Demetris AJ, et al. Oxidative stress and p53 mutations in the carcinogenesis of iron-overload-associated hepatocellular carcinoma. J. Natl. Cancer Inst. 2001;93:1652–1655
  76. Hussain SP, Raja K, Amstad PA, Sawyer M, Trudel TJ, Wogan GN, et al. Increased p53 mutation load in non-tumorous human liver of Wilson disease and haemochromatosis: oxyradical overload disease. Proc. Natl. Acad. Sci. USA. 2000;97:12770–12775
  77. Vadrot N, Legrand A, Nello E, Bringuier AF, Guillot R, Feldman G. Inducible nitric oxide synthase could be responsible for resistance or sensitivity to IFN-gamma-induced apoptosis in several human hepatoma cell lines. J. Interferon Cytokine Res. 2006;26:901–913
  78. Hon WM, Lee KH, Khooo HE. Nitric oxide in liver diseases: friend, foe, or just passer-by?. Ann. N.Y. Acad. Sci. 2002;962:275–295
  79. Kim YM, Chung HT, Simmons RL, Billiar TR. Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition. J. Biol. Chem. 2000;275:10954–10961
  80. Troadec M-B, Courselaud B, Detwaud L, Haziza-Pigeon C, Leroyer P, Brissot P, et al. Iron overload promotes cyclin D1 expression and alters cell cycle in mouse hepatocytes. J. Hepatol. 2006;44:391–399
  81. Green R, Esparza I, Schreiber R. Iron inhibits the non-specific tumoricidal activity of macrophages. A possible contributory mechanism for neoplasia in hemochromatosis. Ann. N.Y. Acad. Sci. 1988;526:301–309
  82. Matzner Y, Hershko C, Polliak K, Konijn A, Izak G. Suppressive effect of ferritin on in vitro lymphocyte function. Br. J. Hematol. 1979;42:443–448
  83. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int. 2003;23:1–5
  84. Asare GA, Bronze M, Naidoo V, Kew MC. Interaction between aflatoxin B1 and dietary iron overload in hepatic mutagenesis. Toxicology. 2007;234:157–166

PII: S0304-3835(08)00874-4

doi: 10.1016/j.canlet.2008.11.001

Cancer Letters
Volume 286, Issue 1 , Pages 38-43 , 1 December 2009

Article Tools